This partnership merges WuXi Biologics' world-class manufacturing capabilities with Earendil's AI-powered drug discovery engine.
This partnership merges WuXi Biologics' world-class manufacturing capabilities with Earendil's AI-powered drug discovery engine. It creates a streamlined path from AI-driven design to clinical production for complex antibodies and ADCs, potentially shortening development timelines and strengthening both companies' positions in the competitive biologics market.
WuXi Biologics provides end-to-end development and manufacturing for Earendil's antibody pipeline
Earendil Labs leverages AI for designing bispecific/multispecific antibodies and ADCs
The collaboration aims to accelerate clinical development and regulatory submissions for new autoimmune and cancer therapies
The collaboration aims to accelerate clinical development and regulatory submissions for new autoimmune and cancer therapies
The deal utilizes WuXi Biologics' proprietary WuXia™ and WuXiHigh™ technology platforms
Sign in to save notes on signals.
Sign In